Here's what we'll cover
Here's what we'll cover
Why Governments Are Pulling Back on Ozempic Coverage
If you're covered through a state or local government employer plan, recent news out of Maryland should be on your radar. A state benefits board voted to cap how much those plans will spend on Ozempic (semaglutide), the blockbuster GLP-1 medication originally approved for type 2 diabetes and widely prescribed for weight management.
Maryland isn't alone. Across the country, public employers, large insurers, and state Medicaid programs are wrestling with the same question: how do you cover a medication that costs over $1,000 per month at list price when tens of millions of people may be eligible for it?
The answer, increasingly, is that they're putting limits on what they'll pay.
What a Spending Cap Actually Means
A spending cap doesn't always mean a flat "no" to coverage. In practice, it can take several forms. Plans may set a maximum annual benefit amount for GLP-1 drugs, require patients to try other medications first (known as step therapy), add stricter prior authorization requirements, or shift more of the cost onto employees through higher copays and coinsurance.
For patients already taking Ozempic or Wegovy (semaglutide for weight loss), the practical effect depends heavily on how your specific plan implements the cap. Some people may see little change. Others could face hundreds of dollars more per month in out-of-pocket costs.
The Real Driver: Cost, Not Effectiveness
It's worth being clear about something. These coverage restrictions are not being driven by doubts about whether GLP-1 medications work. The clinical evidence for semaglutide and tirzepatide (the active ingredient in Mounjaro and Wegovy's cousin, Zepbound) is well-established. Large randomized trials have shown meaningful reductions in body weight, cardiovascular risk, and blood sugar levels.
The issue is purely financial. A single employee on a GLP-1 medication can cost a plan $12,000 to $15,000 per year or more at list price. When a state employs tens of thousands of people, the math gets complicated fast.
According to analysis from the Kaiser Family Foundation, GLP-1 drugs have rapidly become one of the largest drivers of prescription drug spending for employers and insurers. That pressure is showing up in benefits decisions at every level of government.
Why Public Employers Are Especially Affected
Private employers can adjust benefits more quietly and quickly. Public sector benefits are often negotiated, subject to board votes, and politically visible. When a Maryland board votes to cap Ozempic spending, it's news precisely because the process is transparent.
That transparency is actually useful for patients. It gives you a warning, and some lead time to explore your options before a plan change takes effect.
What This Could Mean If You're Currently on a GLP-1
If you're on semaglutide or tirzepatide through a state or local government employer plan, here are the most likely scenarios you might face over the coming months or year.
Talk to your benefits administrator now, before open enrollment or a plan change, to understand exactly what your current coverage looks like and whether any changes are planned.
Questions to Ask Your Doctor if Your Coverage Changes
If your plan reduces or eliminates your GLP-1 coverage, you don't have to simply go without. Here are practical questions worth raising with your prescriber.
Am I eligible for manufacturer savings programs? Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) both offer savings cards and patient assistance programs. Eligibility varies based on insurance status and income, but these programs can dramatically reduce costs for commercially insured patients.
Is compounded semaglutide an option for me? During periods when brand-name medications face supply or access issues, FDA-registered compounding pharmacies have been permitted to produce semaglutide. Compounded versions are significantly cheaper, though they are not FDA-approved products and come with their own considerations. Ask your doctor whether this is appropriate for your situation.
Are there alternative GLP-1 medications covered under my plan? Some plans may cover one GLP-1 but not another. If Ozempic is restricted but tirzepatide or a different formulation remains on formulary, your doctor may be able to adjust your treatment accordingly.
How Telehealth Providers Can Help When Traditional Coverage Falls Short
One of the most important shifts in GLP-1 access over the past few years has been the rise of telehealth-based prescribing. Platforms that specialize in GLP-1 medications can often connect patients with licensed prescribers quickly, and many work directly with compounding pharmacies or negotiate better cash-pay rates.
If your employer coverage becomes restrictive, a telehealth provider may be able to offer a more predictable monthly cost than trying to navigate a fragmented insurance benefit. That said, quality varies significantly across platforms, and you should look carefully at how providers are licensed, what follow-up care looks like, and whether there are hidden fees.
You can compare top-rated options on our Best Providers page, which reviews telehealth platforms specifically for GLP-1 prescribing, cost transparency, and patient support.
The Bigger Picture: A National Trend With Local Consequences
Maryland's board vote is one data point in a much larger pattern. States including North Carolina, Indiana, and West Virginia have previously made headlines for restricting or eliminating GLP-1 coverage in their Medicaid and state employee plans. Several large private insurers have also tightened prior authorization requirements in recent years.
At the federal level, there's been ongoing debate about whether Medicare should cover GLP-1 drugs for obesity (as distinct from diabetes), and what that would cost the program. The Biden administration moved to expand access, while the policy future under subsequent administrations remains uncertain.
The underlying tension is real and unlikely to resolve quickly. GLP-1 medications represent a genuine clinical advance, and yet their current pricing makes broad population-level coverage financially difficult for payers of all types.
What Advocates and Researchers Are Saying
Some health economists argue that the long-term savings from reducing obesity-related conditions (heart disease, sleep apnea, type 2 diabetes, joint disease) could offset the upfront medication costs. Studies published in journals like JAMA and the New England Journal of Medicine support the cardiovascular benefits of semaglutide in particular.
But payers often think in shorter budget cycles, and the upfront costs are borne by the current plan, while long-term health savings may accrue elsewhere in the system. That mismatch continues to drive restrictive coverage decisions, even when the clinical case for treatment is strong.
How to Protect Your Access Right Now
Whether you're currently on a GLP-1 medication or just starting to explore it, there are practical steps you can take now to reduce your vulnerability to coverage changes.
Document your medical need clearly. Work with your doctor to ensure your chart reflects your complete health history, including BMI, comorbid conditions like type 2 diabetes or cardiovascular disease, and any previous weight loss attempts. This documentation is critical for prior authorization appeals.
Appeal denials. If your plan denies coverage, you have the legal right to appeal. Your doctor can submit a letter of medical necessity. Appeals are often successful, particularly when there is a clear clinical rationale.
Explore all savings options. Manufacturer coupons, patient assistance programs, and third-party discount cards can meaningfully reduce what you pay out of pocket. Our GLP-1 Coupons page tracks current savings programs and discount options in one place.
Stay informed about your plan. Read your Summary of Benefits and Coverage document each year during open enrollment. If you're on an expensive specialty medication, it's worth understanding your formulary before you need it.
No waiting list. No insurance needed.
Frequently Asked Questions
Will Maryland's Ozempic spending cap mean I lose my coverage?
Not necessarily. A spending cap limits what the plan pays annually, but doesn't always eliminate coverage entirely. You may face higher out-of-pocket costs once a cap is reached, or encounter new prior authorization steps. Check with your benefits administrator for the specifics of how any cap will be applied.
What can I do if my insurance stops covering Ozempic or Wegovy?
You have several options. Manufacturer savings cards from Novo Nordisk can reduce costs significantly for eligible patients. Telehealth providers may offer access to compounded semaglutide at lower cash-pay prices. You can also appeal a denial with a letter of medical necessity from your doctor.
Is compounded semaglutide safe if I can't afford brand-name Ozempic?
Compounded semaglutide is produced by FDA-registered pharmacies and can be significantly cheaper than the brand-name version, but it is not an FDA-approved product. Effectiveness and quality can vary. Discuss the option carefully with your prescriber before making any switch.
Why are governments cutting Ozempic coverage if it actually works?
The clinical evidence for GLP-1 medications is strong, but the cost is very high. At list price, a year of Ozempic or Wegovy can cost $12,000 to $15,000 per patient. For large public employers covering thousands of employees, the total spending adds up quickly, prompting coverage limits.
Does Medicare cover Ozempic or Wegovy for weight loss?
Medicare currently covers Ozempic when prescribed for type 2 diabetes, but coverage for weight loss alone under Wegovy has been more limited and subject to ongoing policy debate. Rules may vary by plan year, so check your specific Medicare Part D formulary.
How do I appeal if my plan denies my GLP-1 prescription?
Start by requesting a formal written denial from your insurer, which must include the reason for denial. Then ask your doctor to write a letter of medical necessity detailing your diagnosis, previous treatments tried, and why the GLP-1 medication is clinically appropriate. Submit this with your appeal and request an expedited review if needed.